Page last updated: 2024-11-11

rifamycin sv

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rifamycin SV: RN given refers to parent cpd; structure in Merck Index, 9th ed, #8009 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rifamycin SV : A member of the class of rifamycins that exhibits antibiotic and antitubercular properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6324616
CHEMBL ID437765
CHEBI ID29673
CHEBI ID26580
SCHEMBL ID151824
MeSH IDM0081464

Synonyms (66)

Synonym
rifamycine [inn-french]
rifocyn
2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2h)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate
5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2-h)-dione, 21-acetate
rifamicina [inn-spanish]
rifamycin sv, an antibiotic produced by certain strains of streptomyces mediterranei, or the same substance produced by any other means
rifomycin sv
rifamycinum [inn-latin]
rifamicine sv
einecs 230-273-3
D02549
rifamycin (usan/inn)
tuborin
2,7-(epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2h)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2s,16s,17s,18r,19r,20r,21s,22r,23s)-
(pentahydroxy-methoxy-heptamethyl-dioxo-[?]yl) acetate
rifocin
rifamycin sv
rifamycin
rifomycin
LMPK05000005
m-14
chebi:29673 ,
CHEMBL437765
bdbm50391000
rifamycine
rifamycinum
rifamicina
unii-du69t8zzpa
du69t8zzpa ,
rifamycin [usan:inn:ban:dcf]
rifamycin [inn]
rifamycin [usan]
rifamycin sv [ep impurity]
rifaximin impurity c [ep impurity]
rifamycin sv [mi]
5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2h)-dione 21-acetate
rifamycin [who-dd]
gtpl4570
HJYYPODYNSCCOU-ODRIEIDWSA-N
SCHEMBL151824
(2s,12z,14e,16s,17s,18r,19r,20r,21s,22r,23s,24e)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate
AKOS024281286
DTXSID1032014 ,
SR-01000872597-1
sr-01000872597
(7s,11s,13s,17s,18s,12r,14r,15r,16r)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7 ,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<4, 7>.0<5,28>]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
6998-60-3 (free acid)
DB11753
Q26270990
rifamycin-sv
rifamicina (inn-spanish)
rifamycine (inn-french)
(2s,12z,14e,16s,17s,18r,19r,20r,21s,22r,23s,24e)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca(1,11,13)trienoimino)naphtho(2,1-b)furan-21-yl acetate
a07aa13
dtxcid9012014
j04ab03
rifamycin sv (ep impurity)
s02aa12
rifamycinum (inn-latin)
d06ax15
rifaximin impurity c (ep impurity)
chebi:26580
HY-B1907A
CS-0092130

Research Excerpts

Overview

Rifamycin SV is being targeted for the oral treatment of traveler's diarrhea (TD) and Clostridium difficile-associated disease (CDAD) It kills bacteria commonly associated with infectious diarrhea and other enteric infections.

ExcerptReferenceRelevance
"Rifamycin SV (rifamycin), is a member of the ansamycin family of antimicrobial compounds which kills bacteria commonly associated with infectious diarrhea and other enteric infections. "( Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFκB inhibition.
Agan, FJ; Gerloni, M; Hassan, C; Mazzetti, A; Moro, L; Rosette, C; Rosette, N, 2019
)
3.4
"Rifamycin SV is a broad-spectrum, poorly absorbed antimicrobial agent that, when coupled with MMX technology, is being targeted for the oral treatment of traveler's diarrhea (TD) and Clostridium difficile-associated disease (CDAD). "( In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Biedenbach, DJ; Bozzella, R; Celasco, G; Farrell, DJ; Jones, RN; Moro, L; Putnam, SD, 2011
)
2.06
"Rifamycin SV is an antibiotic anti-bacterial agent used in the treatment of tuberculosis. "( Stimulation of NADH-dependent microsomal DNA strand cleavage by rifamycin SV.
Cederbaum, AI; Kukiełka, E, 1995
)
1.97

Pharmacokinetics

ExcerptReferenceRelevance
" Compared with a control group, the alteration of the half-life both of NA and R-SV was less marked in GS1 than in GS2."( Impaired plasma clearance of nicotinic acid and rifamycin-SV in Gilbert's syndrome: evidence of a functional heterogeneity.
Bronzino, P; Coltorti, M; Gentile, S; Marmo, R; Persico, M, 1985
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

Rifamycin SV is a broad-spectrum, poorly absorbed antimicrobial agent. It is being targeted for the oral treatment of traveler's diarrhea (TD) and Clostridium difficile-associated disease (CDAD)

ExcerptReferenceRelevance
" While compounds 1-5 had poor antibacterial activity in vitro, compounds 6-11 were found to be highly active in vitro but poorly absorbed in vivo."( The synthesis of 4-deoxypyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV derivatives.
Brufani, M; Cellai, L; Marchi, E; Segre, A, 1984
)
0.51
" The data indicate that these inhibitors can be used to determine the in vivo relevance of Oatp1 and Oatp2 for the overall bioavailability and disposition of drugs and other Oatp1/2 substrates."( Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2.
Cattori, V; Fattinger, K; Hagenbuch, B; Meier, PJ; Stieger, B, 2000
)
1.75
" bioavailability in preclinical species and humans."( Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
Davis, CB; Dawson, PA; Garver, E; Han, C; Hugger, ED; Rao, A; Shearn, SP, 2008
)
0.35
"Rifamycin SV is a broad-spectrum, poorly absorbed antimicrobial agent that, when coupled with MMX technology, is being targeted for the oral treatment of traveler's diarrhea (TD) and Clostridium difficile-associated disease (CDAD)."( In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Biedenbach, DJ; Bozzella, R; Celasco, G; Farrell, DJ; Jones, RN; Moro, L; Putnam, SD, 2011
)
2.06
" Thus, a study was designed to compare this poorly absorbed antibiotic with the systemic agent ciprofloxacin."( Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.
Araujo, P; DuPont, HL; Gracias Garcia, ML; Greinwald, R; Jiang, ZD; Nacak, T; Steffen, R; Stiess, M, 2018
)
1.92
"The novel multi-matrix formulation of the broad-spectrum, poorly absorbed antibiotic Rifamycin SV was found non-inferior to the systemic antibiotic ciprofloxacin in the oral treatment of non-dysenteric TD with the advantage of a lower risk of ESBL-E."( Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.
Araujo, P; DuPont, HL; Gracias Garcia, ML; Greinwald, R; Jiang, ZD; Nacak, T; Steffen, R; Stiess, M, 2018
)
2.15

Dosage Studied

ExcerptRelevanceReference
" Oral administration of rifampin at three times the intra-articular dosage was devoid of any therapeutic activity."( Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints.
Caruso, I; Cazzola, M; Santandrea, S, 1992
)
0.53
" The weekly dosage of Rifamycin SV was 500 mg; the average duration of treatment was 6 weeks."( The treatment of idiopathic and secondary hydrarthrosis of the knee by intra-articular Rifamycin SV.
Calciolari, CA; Cimino, V; Sarzi Puttini, P; Setti, G; Zanini, A,
)
0.67
" The ability to measure rifampicin drug concentrations in both plasma and in cells may be useful in evaluating the suitability of dosage regimens for populations and individuals."( A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin.
Ardrey, A; Ashleigh, S; Back, DJ; Chaponda, M; Davies, G; Hartkoorn, RC; Khoo, S; Tjia, JF; Waitt, CJ; Ward, SA, 2007
)
0.34
" The results demonstrated that simultaneous administration of α-AMA and each of tested antidotes (BPCN, CEFT, RIFSV) effectively protected human hepatocytes; however, in the group dosed with BPCN, the highest hepatocyte viability was observed."( Comparative antidotal efficacy of benzylpenicillin, ceftazidime and rifamycin in cultured human hepatocytes intoxicated with α-amanitin.
Dziędgiel, P; Gomułkiewicz, A; Magdalan, J; Ostrowska, A; Piotrowska, A; Szeląg, A, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antitubercular agentA substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
rifamycins
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
macrocycleA cyclic compound containing nine or more atoms as part of the cyclic system.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Ki7.30000.03702.34107.3000AID680348
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)3.10000.40002.75008.6000AID1209456
Bile salt export pumpRattus norvegicus (Norway rat)Ki3.80000.30003.10006.1000AID679145
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)Ki3.00000.53004.11578.4800AID679448
Bile salt export pumpHomo sapiens (human)IC50 (µMol)58.62500.11007.190310.0000AID1209455; AID1443986; AID681139; AID681155
Bile salt export pumpHomo sapiens (human)Ki31.00007.00008.25009.5000AID680939
DNA-directed RNA polymerase subunit betaEscherichia coli K-12IC50 (µMol)50.01000.02000.02500.0300AID1802841
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Ki6.60001.10004.51259.8000AID680468
DNA-directed RNA polymerase subunit betaShigella sonnei Ss046IC50 (µMol)50.01000.02000.02500.0300AID1802841
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki3.00000.08002.46889.8000AID679646
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)0.23000.05002.37979.7000AID681366
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki2.00000.04401.36305.0000AID679507
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (90)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
DNA-templated transcriptionDNA-directed RNA polymerase subunit betaEscherichia coli K-12
DNA-templated transcription initiationDNA-directed RNA polymerase subunit betaEscherichia coli K-12
intracellular iron ion homeostasisDNA-directed RNA polymerase subunit betaEscherichia coli K-12
response to heatDNA-directed RNA polymerase subunit betaEscherichia coli K-12
transcription antiterminationDNA-directed RNA polymerase subunit betaEscherichia coli K-12
regulation of DNA-templated transcription elongationDNA-directed RNA polymerase subunit betaEscherichia coli K-12
cellular response to cell envelope stressDNA-directed RNA polymerase subunit betaEscherichia coli K-12
nitrate assimilationDNA-directed RNA polymerase subunit betaEscherichia coli K-12
bacterial-type flagellum assemblyDNA-directed RNA polymerase subunit betaEscherichia coli K-12
response to antibioticDNA-directed RNA polymerase subunit betaEscherichia coli K-12
cell motilityDNA-directed RNA polymerase subunit betaEscherichia coli K-12
bacterial-type flagellum-dependent cell motilityDNA-directed RNA polymerase subunit betaEscherichia coli K-12
submerged biofilm formationDNA-directed RNA polymerase subunit betaEscherichia coli K-12
regulation of DNA-templated transcription initiationDNA-directed RNA polymerase subunit betaEscherichia coli K-12
negative regulation of transcription by RNA polymerase IIB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIB-cell lymphoma 6 proteinHomo sapiens (human)
cell morphogenesisB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of cell-matrix adhesionB-cell lymphoma 6 proteinHomo sapiens (human)
plasma cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
germinal center formationB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of germinal center formationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of B cell apoptotic processB-cell lymphoma 6 proteinHomo sapiens (human)
transcription by RNA polymerase IIB-cell lymphoma 6 proteinHomo sapiens (human)
inflammatory responseB-cell lymphoma 6 proteinHomo sapiens (human)
DNA damage responseB-cell lymphoma 6 proteinHomo sapiens (human)
cell-matrix adhesionB-cell lymphoma 6 proteinHomo sapiens (human)
Rho protein signal transductionB-cell lymphoma 6 proteinHomo sapiens (human)
spermatogenesisB-cell lymphoma 6 proteinHomo sapiens (human)
protein localizationB-cell lymphoma 6 proteinHomo sapiens (human)
pyramidal neuron differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
actin cytoskeleton organizationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of cell growthB-cell lymphoma 6 proteinHomo sapiens (human)
positive regulation of B cell proliferationB-cell lymphoma 6 proteinHomo sapiens (human)
heterochromatin formationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of mast cell cytokine productionB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of mononuclear cell proliferationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of Rho protein signal transductionB-cell lymphoma 6 proteinHomo sapiens (human)
B cell proliferationB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of T cell proliferationB-cell lymphoma 6 proteinHomo sapiens (human)
positive regulation of apoptotic processB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of memory T cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
T-helper 2 cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
positive regulation of regulatory T cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of T-helper 2 cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
positive regulation of neuron differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of Notch signaling pathwayB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of DNA-templated transcriptionB-cell lymphoma 6 proteinHomo sapiens (human)
isotype switching to IgE isotypesB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of isotype switching to IgE isotypesB-cell lymphoma 6 proteinHomo sapiens (human)
erythrocyte developmentB-cell lymphoma 6 proteinHomo sapiens (human)
cell motilityB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of immune responseB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of plasma cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of mitotic cell cycle DNA replicationB-cell lymphoma 6 proteinHomo sapiens (human)
positive regulation of cell motilityB-cell lymphoma 6 proteinHomo sapiens (human)
negative regulation of cellular senescenceB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of cytokine productionB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of immune system processB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of inflammatory responseB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of cell differentiationB-cell lymphoma 6 proteinHomo sapiens (human)
regulation of cell population proliferationB-cell lymphoma 6 proteinHomo sapiens (human)
type 2 immune responseB-cell lymphoma 6 proteinHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
DNA bindingDNA-directed RNA polymerase subunit betaEscherichia coli K-12
DNA-directed 5'-3' RNA polymerase activityDNA-directed RNA polymerase subunit betaEscherichia coli K-12
protein bindingDNA-directed RNA polymerase subunit betaEscherichia coli K-12
nucleotidyltransferase activityDNA-directed RNA polymerase subunit betaEscherichia coli K-12
ribonucleoside bindingDNA-directed RNA polymerase subunit betaEscherichia coli K-12
5'-3' RNA polymerase activityDNA-directed RNA polymerase subunit betaEscherichia coli K-12
DNA-directed 5'-3' RNA polymerase activityDNA-directed RNA polymerase subunit betaEscherichia coli K-12
intronic transcription regulatory region sequence-specific DNA bindingB-cell lymphoma 6 proteinHomo sapiens (human)
transcription corepressor bindingB-cell lymphoma 6 proteinHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificB-cell lymphoma 6 proteinHomo sapiens (human)
chromatin bindingB-cell lymphoma 6 proteinHomo sapiens (human)
DNA-binding transcription factor activityB-cell lymphoma 6 proteinHomo sapiens (human)
protein bindingB-cell lymphoma 6 proteinHomo sapiens (human)
chromatin DNA bindingB-cell lymphoma 6 proteinHomo sapiens (human)
identical protein bindingB-cell lymphoma 6 proteinHomo sapiens (human)
sequence-specific DNA bindingB-cell lymphoma 6 proteinHomo sapiens (human)
metal ion bindingB-cell lymphoma 6 proteinHomo sapiens (human)
DNA-binding transcription factor bindingB-cell lymphoma 6 proteinHomo sapiens (human)
sequence-specific double-stranded DNA bindingB-cell lymphoma 6 proteinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingB-cell lymphoma 6 proteinHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmDNA-directed RNA polymerase subunit betaEscherichia coli K-12
cytosolDNA-directed RNA polymerase subunit betaEscherichia coli K-12
membraneDNA-directed RNA polymerase subunit betaEscherichia coli K-12
cytosolic DNA-directed RNA polymerase complexDNA-directed RNA polymerase subunit betaEscherichia coli K-12
DNA-directed RNA polymerase complexDNA-directed RNA polymerase subunit betaEscherichia coli K-12
replication forkB-cell lymphoma 6 proteinHomo sapiens (human)
nucleusB-cell lymphoma 6 proteinHomo sapiens (human)
nucleoplasmB-cell lymphoma 6 proteinHomo sapiens (human)
nucleolusB-cell lymphoma 6 proteinHomo sapiens (human)
Golgi apparatusB-cell lymphoma 6 proteinHomo sapiens (human)
paraspecklesB-cell lymphoma 6 proteinHomo sapiens (human)
nucleoplasmB-cell lymphoma 6 proteinHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (115)

Assay IDTitleYearJournalArticle
AID70791In vitro antibacterial activity of compound against Escherichia coli SKF 121401990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID163581In vitro antibacterial activity of compound against Proteus vulgaris X19H ATCC 8811990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID94362In vitro antibacterial activity of compound against Klebsiella pneumoniae ISM1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID301528Antibacterial activity against rifamycin-resistance Staphylococcus aureus CB3702007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
AID1154544Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 C387S mutant assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID14138950% inhibition of the 20 Mycobacterium (MAC) avium complex clinical isolates; No data1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID205648Antibacterial activity against Staphylococcus aureus 10B1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID29851Half life was measured as time taken to decrease half of its initial concentration2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID69354Minimum inhibitory concentration of compound tested for antibacterial activity against Escherichia coli ML/351981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antibacterial activity of some ester, amides, and hydrazides of 3-carboxyrifamycin S. Relationship between structure and activity of ansamycins.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1146809Antibacterial activity against Klebsiella pneumoniae Ottaviani assessed as inhibition of visible growth after 24 hrs by serial dilution method1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis and antibacterial activity of some derivatives of tolypomycinone. Relationship between structure and activity in ansamycins.
AID1154547Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 Rv1937/F426C mutant assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID201070Activity in the murine model (OS route) of Staphylococcus aureus tour septicemia1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID301526Antibacterial activity against rifamycin-sensitive Staphylococcus aureus CB190 ATCC 292132007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID69990The compound is evaluated for inhibitory concentration against Escherichia coli and is expressed as minimum inhibitory concentration (MIC).1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O.
AID1154542Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID94213Minimum inhibitory concentration of compound tested for antibacterial activity against Klebsiella pneumoniae ottaviani1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antibacterial activity of some ester, amides, and hydrazides of 3-carboxyrifamycin S. Relationship between structure and activity of ansamycins.
AID680468TP_TRANSPORTER: inhibition of E217betaG uptake in Xenopus laevis oocytes2000Hepatology (Baltimore, Md.), Jul, Volume: 32, Issue:1
Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2.
AID681139TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID679957TP_TRANSPORTER: inhibition of BSP uptake in Xenopus laevis oocytes2002Hepatology (Baltimore, Md.), Jul, Volume: 36, Issue:1
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
AID738687Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin assay2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis and biological evaluation of trans 6-methoxy-1,1-dimethyl-2-phenyl-3-aryl-2,3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating M. tuberculosis H37Rv and clinical multidrug resistant strains.
AID1163450Growth inhibition of human Breast cancer cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID1163447Growth inhibition of human Ovarian cancer cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID681155TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID168261Tested for hypolipidemic activity in male rats, cholesterol was determined in serum at 50 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID680348TP_TRANSPORTER: inhibition of E217betaG uptake in Xenopus laevis oocytes2000Hepatology (Baltimore, Md.), Jul, Volume: 32, Issue:1
Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID14138650% inhibition of the 20 Mycobacterium (MAC) avium complex clinical isolates1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID679145TP_TRANSPORTER: inhibition of Taurocholate uptake in membrane vesicles from Bsep-expressing Sf9 cells2000Gastroenterology, Feb, Volume: 118, Issue:2
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
AID163949In vitro antibacterial activity of compound against Pseudomonas aeruginosa ATCC 101451990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID141385Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID680939TP_TRANSPORTER: inhibition of Taurocholate uptake(Rifampicin SV 30uM, 50 % of control) in membrane vesicles prepared from High Five cells infected with the ABCB11 baculovirus2002Gastroenterology, Nov, Volume: 123, Issue:5
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID201407In vitro antibacterial activity of compound against Staphylococcus aureus Tour L 1651990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1154545Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 C387G mutant assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID1146808Antibacterial activity against Staphylococcus aureus 209 P(FDA) assessed as inhibition of visible growth after 24 hrs by serial dilution method1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis and antibacterial activity of some derivatives of tolypomycinone. Relationship between structure and activity in ansamycins.
AID679507TP_TRANSPORTER: inhibition of BSP uptake in Xenopus laevis oocytes2002Hepatology (Baltimore, Md.), Jul, Volume: 36, Issue:1
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
AID738686Lipophilicity, log P of the compound2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis and biological evaluation of trans 6-methoxy-1,1-dimethyl-2-phenyl-3-aryl-2,3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating M. tuberculosis H37Rv and clinical multidrug resistant strains.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID208937In vitro antibacterial activity of compound against Streptococcus pneumoniae UC 411990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID201071Activity in the murine model (subcutaneous route) of Staphylococcus aureus tour septicemia1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID200519Minimum inhibitory concentration of compound tested for antibacterial activity against Salmonella paratyphi BO 248 K(Sclavo)1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antibacterial activity of some ester, amides, and hydrazides of 3-carboxyrifamycin S. Relationship between structure and activity of ansamycins.
AID53305Inhibitory concentration against DNA dependent RNA polymerase in Escherichia coli1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O.
AID1163445Growth inhibition of human CNS cancer cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID322956Inhibition of synthetic amyloid beta42 oligomer formation by Western blot2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID679646TP_TRANSPORTER: inhibition of BSP uptake in Xenopus laevis oocytes2002Hepatology (Baltimore, Md.), Jul, Volume: 36, Issue:1
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
AID301527Antibacterial activity against rifamycin-resistance Staphylococcus aureus CB3722007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
AID738688Antimicrobial activity against Mycobacterium tuberculosis H37Rv by BACTEC radiometric method2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis and biological evaluation of trans 6-methoxy-1,1-dimethyl-2-phenyl-3-aryl-2,3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating M. tuberculosis H37Rv and clinical multidrug resistant strains.
AID1163443Growth inhibition of human Leukemia cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID681366TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells2005Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
AID584269Inhibition of Escherichia coli RNA polymerase using Kool NC-45 universal RNA polymerase template2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase.
AID738685Selectivity index, ratio of CC50 for african green monkey Vero cells tp MIC for Mycobacterium tuberculosis H37Rv2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis and biological evaluation of trans 6-methoxy-1,1-dimethyl-2-phenyl-3-aryl-2,3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating M. tuberculosis H37Rv and clinical multidrug resistant strains.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1163444Growth inhibition of human Colon cancer cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID1154546Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 Y314H mutant assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID1146810Antibacterial activity against Escherichia coli MC/35 assessed as inhibition of visible growth after 24 hrs by serial dilution method1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis and antibacterial activity of some derivatives of tolypomycinone. Relationship between structure and activity in ansamycins.
AID1483212Binding affinity to 6His-tagged human BCL6 BTB domain (7 to 128 amino acid residues) expressed in Escherichia coli Rosetta (DE3) after 1 min by fluorescence polarization assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
AID275411Inhibition of DNA dependent RNA polymerase in prokaryotes2007Journal of natural products, Jan, Volume: 70, Issue:1
Saliniketals A and B, bicyclic polyketides from the marine actinomycete Salinispora arenicola.
AID144208In vitro antibacterial activity of compound against Neisseria gonorrhoeae ISM 68/1261990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID1154543Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 OE mutant assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID104012In vitro antibacterial activity of compound against Mycobacterium tuberculosis H37Rv ATCC 96601990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID682141TP_TRANSPORTER: increase in Calcein intracellular accumulation (Calcein: 0.5 uM, Rifamycin SV: 200 uM) in GLC4/ADR cells1999Cancer letters, May-03, Volume: 139, Issue:1
Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells.
AID168879Hypolipidemic activity was determined in male rats, and high-density lipoprotein level was determined at 50 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID79580In vitro antibacterial activity of compound against Haemophilus influenzae ATCC 194181990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID679448TP_TRANSPORTER: inhibition of BSP uptake in Xenopus laevis oocytes2002Hepatology (Baltimore, Md.), Jul, Volume: 36, Issue:1
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
AID680731TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 2 uM, Rifamycin SV: 50 uM) in OATP-C-expressing HEK293 cells2001The Journal of biological chemistry, Mar-30, Volume: 276, Issue:13
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.
AID206207In vitro antibacterial activity of compound against Staphylococcus epidermidis ATCC 122281990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID1146811Antibacterial activity against Salmonella paratyphi B 0248 K assessed as inhibition of visible growth after 24 hrs by serial dilution method1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis and antibacterial activity of some derivatives of tolypomycinone. Relationship between structure and activity in ansamycins.
AID168884Hypolipidemic activity was determined in male rats, and low-density lipoprotein level was determined at 50 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID202132In vitro antibacterial activity of compound against Streptococcus pyogenes C 203 SKF 134001990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID207982Minimum inhibitory concentration of compound tested for antibacterial activity against Staphylococcus aureus 209 P(FDA)1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Synthesis and antibacterial activity of some ester, amides, and hydrazides of 3-carboxyrifamycin S. Relationship between structure and activity of ansamycins.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID30135Volume of distribution of the compound2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID1163448Growth inhibition of human Renal cancer cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID680217TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 2 uM, Rifamycin SV: 50 uM) in OATP8-expressing HEK293 cells2001The Journal of biological chemistry, Mar-30, Volume: 276, Issue:13
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.
AID27900Plasma clearance of the compound2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID1163446Growth inhibition of human Melanoma cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID681664TP_TRANSPORTER: inhibition of Taurochenodeoxycholate-stimulated ATPase activity (Rifamycin SV: 100 uM) in membrane vesicles from Bsep-expressing Sf9 cells2001Hepatology (Baltimore, Md.), May, Volume: 33, Issue:5
Characterization of the mouse bile salt export pump overexpressed in the baculovirus system.
AID1163449Growth inhibition of human Prostate cancer cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID680461TP_TRANSPORTER: inhibition of Gadoxetate uptake (Gadoxetate: 100 uM, Rifamycin SV: 100 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jul, Volume: 290, Issue:1
Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID681461TP_TRANSPORTER: increase in Vinblastine intracellular accumulation (Vinblastine: 0.0125 uM, Rifamycin SV: 200 uM) in RHC1 cells1995Biochemical pharmacology, May-11, Volume: 49, Issue:9
Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID209408In vitro antibacterial activity of compound against Streptococcus faecalis ATCC 7080.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and biological activity of some derivatives of rifamycin P.
AID1163442Growth inhibition of human NSCLC cells2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1345178Human OATP1B1 (SLCO family of organic anion transporting polypeptides)2002Hepatology (Baltimore, Md.), Jul, Volume: 36, Issue:1
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
AID1345149Human OATP1A2 (SLCO family of organic anion transporting polypeptides)2002Hepatology (Baltimore, Md.), Jul, Volume: 36, Issue:1
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
AID1802841RNAP-Inhibition Assay from Article 10.1021/acschembio.6b01133: \\Affinity Selection-Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor.\\2017ACS chemical biology, 05-19, Volume: 12, Issue:5
Affinity Selection-Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (327)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990196 (59.94)18.7374
1990's34 (10.40)18.2507
2000's37 (11.31)29.6817
2010's57 (17.43)24.3611
2020's3 (0.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.42 (24.57)
Research Supply Index6.10 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index38.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (2.30%)5.53%
Reviews10 (2.30%)6.00%
Case Studies12 (2.76%)4.05%
Observational0 (0.00%)0.25%
Other402 (92.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study [NCT03447821]Phase 240 participants (Actual)Interventional2008-02-29Completed
Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT). [NCT03528915]881 participants (Actual)Observational2015-09-09Completed
Evaluation of the Effects of Irrigation of the Extraction Socket With Rifamycine on Postoperative Pain, Edema and Trismus in Impacted Lower Third Molar Surgery [NCT04349579]Phase 435 participants (Actual)Interventional2018-11-15Active, not recruiting
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea [NCT01142089]Phase 3264 participants (Actual)Interventional2010-05-27Completed
A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial) [NCT04082780]Phase 230 participants (Actual)Interventional2019-09-01Completed
A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticuliti [NCT01847664]Phase 2204 participants (Actual)Interventional2013-08-31Completed
A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) [NCT04501380]Phase 230 participants (Anticipated)Interventional2020-06-30Enrolling by invitation
A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Tr [NCT01208922]Phase 3835 participants (Actual)Interventional2010-11-30Completed
Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers. Single and Multiple Dose, Open Label, Pharmacokinetics and Safety Study [NCT02969252]Phase 118 participants (Actual)Interventional2015-07-31Completed
Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years [NCT04026984]Phase 2142 participants (Anticipated)Interventional2024-06-30Not yet recruiting
The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study [NCT05588492]Phase 4500 participants (Anticipated)Interventional2022-01-01Recruiting
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome [NCT03099785]Phase 2279 participants (Actual)Interventional2017-12-18Completed
Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years [NCT04027894]Phase 2142 participants (Anticipated)Interventional2024-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01142089 (2) [back to overview]Clinical Cure
NCT01142089 (2) [back to overview]Time to Last Unformed Stool (TLUS)
NCT01208922 (2) [back to overview]Number of Patients With Clinical Cure
NCT01208922 (2) [back to overview]Time to Last Unformed Stool (TLUS)
NCT03447821 (2) [back to overview]Time to Last Unformed Stool (TLUS)
NCT03447821 (2) [back to overview]The Number of Unformed Stools Passed Per 24-h Interval

Clinical Cure

"Clinical Cure is defined as either of the following:~Passage of two or fewer soft stools and no watery stools, no fever (>100.4 ºF or 38 ºC), and no signs or symptoms of enteric infection (other than mild excess gas/flatulence) during a 24 hour interval in the 120-hr data collection period after the first dose of study drug~Passage of no stools or only formed stools and no fever during a 48-hour interval in the 120-hr data collection period after the first dose of study drug, with or without other signs or symptoms of enteric infection" (NCT01142089)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Placebo35
Rifamycin SV MMX162

[back to top]

Time to Last Unformed Stool (TLUS)

"The primary endpoint is TLUS defined as the interval in hours between the first dose of study drug and the last unformed stool passed just before the start of Clinical Cure. An unformed stool is defined as either a soft or watery stool. TLUS will be calculated for each patient in the following manner:~Step 1: Identify when the patient achieves Clinical Cure.~Step 2: Moving backwards from this time, identify the time of the last unformed stool.~Step 3: The TLUS equals the time from the first dose of study drug to the time of the last unformed stool identified in Step 2." (NCT01142089)
Timeframe: 24 hours

,
InterventionTLUS (hours) (Mean)
25th percentile50th percentile75th percentile
Placebo37.468NA
Rifamycin SV MMX21.4672.2

[back to top]

Number of Patients With Clinical Cure

Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection. (NCT01208922)
Timeframe: 5 days

InterventionParticipants (Count of Participants)
Group A357
Group B352

[back to top]

Time to Last Unformed Stool (TLUS)

Time to Last Unformed Stool (TLUS), defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared. (NCT01208922)
Timeframe: 5 days

Interventionhours (Median)
Group A44.3
Group B40.3

[back to top]

Time to Last Unformed Stool (TLUS)

The safety and preliminary efficacy data of the three doses of the new rifamycin SV formulation tested based upon the time elapsed from the ingestion of the 1st dose of study medication to the passage of the last unformed stool (TLUS) (NCT03447821)
Timeframe: Up to 7 days

Interventionhours (Mean)
400 mg Rifamycin SV Dosage59.3
800 mg Rifamycin SV Dosage51.4
1200 mg Rifamycin SV Dosage57.4

[back to top]

The Number of Unformed Stools Passed Per 24-h Interval

The number of unformed stools passed per 24-h interval, after dosing (NCT03447821)
Timeframe: 192 hours

,,
InterventionUnformed stools (Mean)
0-24 h24-48 h48-72 h72-96 h96-120 h120-144 h144-168 h168-192 h
1200 mg Rifamycin SV Dosage4.732.641.71.80.75111
400 mg Rifamycin SV Dosage5.232.152.091.51.5330
800 mg Rifamycin SV Dosage4.671.51.291.671.50.511

[back to top]